SYRA vs. BIAF, MRIN, ISPC, STAF, TC, LYT, DKDCA, HAO, LICN, and TNMG
Should you be buying Syra Health stock or one of its competitors? The main competitors of Syra Health include bioAffinity Technologies (BIAF), Marin Software (MRIN), iSpecimen (ISPC), Staffing 360 Solutions (STAF), TuanChe (TC), Lytus Technologies Holdings PTV. (LYT), Data Knights Acquisition (DKDCA), Haoxi Health Technology (HAO), Lichen China (LICN), and TNL Mediagene - Ordinary Shares (TNMG). These companies are all part of the "business services" industry.
Syra Health vs.
bioAffinity Technologies (NASDAQ:BIAF) and Syra Health (NASDAQ:SYRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
bioAffinity Technologies has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500. Comparatively, Syra Health has a beta of 3.98, suggesting that its share price is 298% more volatile than the S&P 500.
bioAffinity Technologies received 1 more outperform votes than Syra Health when rated by MarketBeat users.
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 4.8% of Syra Health shares are held by institutional investors. 35.1% of bioAffinity Technologies shares are held by insiders. Comparatively, 10.2% of Syra Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Syra Health has a net margin of -54.90% compared to bioAffinity Technologies' net margin of -91.22%. Syra Health's return on equity of -131.94% beat bioAffinity Technologies' return on equity.
Syra Health has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.
bioAffinity Technologies presently has a consensus target price of $6.00, suggesting a potential upside of 2,079.44%. Given bioAffinity Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe bioAffinity Technologies is more favorable than Syra Health.
In the previous week, Syra Health had 2 more articles in the media than bioAffinity Technologies. MarketBeat recorded 2 mentions for Syra Health and 0 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 0.00 beat Syra Health's score of -0.36 indicating that bioAffinity Technologies is being referred to more favorably in the media.
Summary
Syra Health beats bioAffinity Technologies on 9 of the 16 factors compared between the two stocks.
Get Syra Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syra Health Competitors List
Related Companies and Tools
This page (NASDAQ:SYRA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SYRA Stock Free SYRA Stock Alerts